 MENLO PARK, Calif., March 24, 2021 GLOBE NEWSWIRE -- 180 Life Sciences Corp. NASDAQ: ATNF, the Company, a clinical-stage biotechnology company with its lead indication in Phase 2b3 clinical trial, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today released the following letter to stockholders from its Chief Executive Officer, Dr. James Woody. 